ProKidney (NASDAQ:PROK – Get Free Report) and Candel Therapeutics (NASDAQ:CADL – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk.
Risk and Volatility
ProKidney has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.95, suggesting that its stock price is 195% less volatile than the S&P 500.
Profitability
This table compares ProKidney and Candel Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProKidney | N/A | N/A | -10.24% |
| Candel Therapeutics | N/A | -629.29% | -173.39% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProKidney | $76,000.00 | 1,925.64 | -$35.47 million | ($0.63) | -0.79 |
| Candel Therapeutics | $120,000.00 | 1,714.24 | -$37.94 million | ($1.75) | -2.49 |
ProKidney has higher earnings, but lower revenue than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and price targets for ProKidney and Candel Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProKidney | 0 | 2 | 2 | 0 | 2.50 |
| Candel Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
ProKidney currently has a consensus price target of $5.00, indicating a potential upside of 900.00%. Candel Therapeutics has a consensus price target of $21.00, indicating a potential upside of 382.20%. Given ProKidney’s higher probable upside, equities analysts clearly believe ProKidney is more favorable than Candel Therapeutics.
Institutional & Insider Ownership
51.6% of ProKidney shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 41.5% of ProKidney shares are held by insiders. Comparatively, 41.6% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
ProKidney beats Candel Therapeutics on 9 of the 13 factors compared between the two stocks.
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
About Candel Therapeutics
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
